CA Patent

CA2935013C — Pharmaceutical composition containing nitisinone, and its use

Assigned to Cycle Pharmaceuticals Ltd · Expires 2022-08-02 · 4y expired

What this patent protects

Disclosed are oral pharmaceutical compositions consisting of nitisinone, lactose, and glyceryl dibehenate, and their use in the treatment of tyrosinemia, such as Hereditary Tyrosinemia type-1 (HT-1), or alkaptonuria.

USPTO Abstract

Disclosed are oral pharmaceutical compositions consisting of nitisinone, lactose, and glyceryl dibehenate, and their use in the treatment of tyrosinemia, such as Hereditary Tyrosinemia type-1 (HT-1), or alkaptonuria.

Drugs covered by this patent

Patent Metadata

Patent number
CA2935013C
Jurisdiction
CA
Classification
—
Expires
2022-08-02
Drug substance claim
No
Drug product claim
No
Assignee
Cycle Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.